TY  - JOUR
T1  - INfliximab-induced lupus erythematosus tumidus in a patient with rheumatoid arthritis
AU  - Schneider SW, Staender S, Schlüter B, Luger TA, Bonsmann G
Y1  - 2006/01/01
N1  - 10.1001/archderm.142.1.115
JO  - Archives of Dermatology
SP  - 109
EP  - 116
VL  - 142
IS  - 1
N2  - 
Infliximab is a chimeric mouse-human monoclonal antibody targeting tumor necrosis factor α. It is approved for the treatment of refractory rheumatoid arthritis (RA), Crohn disease, ankylosing spondylitis, and psoriatic arthritis. Infliximab usually is well tolerated and has a good safety profile; only rare cases of severe adverse effects, including cardiac failure or mycobacterial infections, have been reported.1 A frequently observed and striking laboratory finding is the development of antinuclear antibodies, usually without clinical lupuslike symptoms.2

SN  - 0003-987X
M3  - doi: 10.1001/archderm.142.1.115
UR  - http://dx.doi.org/10.1001/archderm.142.1.115
ER  -